{"id":18688,"date":"2026-06-10T11:00:00","date_gmt":"2026-06-10T09:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=80381e84b7fc2e17105cc6a472de27a4"},"modified":"2026-06-10T11:00:00","modified_gmt":"2026-06-10T09:00:00","slug":"sofinnova-partners-launches-collaboration-with-aws-to-scale-ai-across-life-sciences-innovation","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18688","title":{"rendered":"Sofinnova Partners Launches Collaboration with AWS to Scale AI Across Life Sciences Innovation"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>Sofinnova combines its sector expertise with AWS\u2019s AI and cloud services to help life sciences companies scale faster<\/i><\/li>\n<li>\n<i>The collaboration expands Sofinnova\u2019s proprietary AI platform, Sofia, including a new founder-facing version<\/i><\/li>\n<\/ul><p>PARIS--(BUSINESS WIRE)--Sofinnova Partners (\u201cSofinnova\u201d), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration with Amazon Web Services (AWS), to embed AI more deeply across its investment platform and portfolio companies.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260609982334\/en\/2102515\/5\/SOFINNOVA_PARTNERS_RVB_noir.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260609982334\/en\/2102515\/22\/SOFINNOVA_PARTNERS_RVB_noir.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260609982334\/en\/2102515\/5\/SOFINNOVA_PARTNERS_RVB_noir.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260609982334\/en\/2102515\/21\/SOFINNOVA_PARTNERS_RVB_noir.jpg\" \/><\/a><p>\nThe collaboration supports Sofinnova.AI, the firm\u2019s initiative to integrate AI across its core activities, from sourcing and evaluating investments to supporting company building. At the center of this effort is <i>Sofia<\/i>, Sofinnova's proprietary AI platform, which will be extended beyond internal use to include a founder-facing version.<\/p><p>\nThrough this collaboration, Sofinnova-backed startups will gain access to tailored AWS resources and technical enablement, helping them move faster from early research to development and commercialization.<\/p><p>\n\u201cAI is becoming central to how new therapies are discovered, developed, and brought to patients,\u201d said <b>Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners<\/b>. \u201cWith Sofinnova.AI and <i>Sofia<\/i>, we are building capabilities that strengthen both our investment approach and the companies we back. Working with AWS reflects both the maturity of this effort and our conviction that the next generation of life sciences leaders will be built differently.\u201d<\/p><p>\nLife sciences companies face real barriers in adopting AI, from infrastructure costs to fragmented tools and workflows. This collaboration addresses this by combining Sofinnova's sector knowledge and <i>Sofia<\/i> with AWS's secure, scalable cloud services built specifically for the life sciences industry, making these tools more accessible and practical for founders.<\/p><p>\n\u201cWe are proud to support the future of life sciences innovation through this collaboration,\u201d said <b>Dan Sheeran, VP and General Manager, Healthcare and Life Sciences at AWS<\/b>. \u201cAWS has worked closely with the pharmaceutical and life sciences industry for nearly two decades, with 19 of the top 20 global pharmaceutical companies trusting us to power their most sensitive research workloads. By combining AWS\u2019s industry-specific services and solutions with Sofinnova\u2019s track record in building life sciences companies, this effort aims to help bring new therapies and solutions to market faster and at scale.\u201d<\/p><p>\nA core part of the collaboration is the development of a founder-facing version of <i>Sofia<\/i>, built on AWS. Until now, <i>Sofia<\/i> has been used internally across Sofinnova\u2019s strategies to analyze deal flow and generate insights across biotech, medtech, digital health, and sustainability. The expanded platform will give founders access to AI-driven tools for competitive landscape analysis, asset benchmarking, and partnership and licensing insights.<\/p><p>\nThese workflows remain largely manual across the industry. By making them faster and more consistent, Sofinnova aims to help companies focus resources on scientific and clinical progress.<\/p><p>\nAs demand for AI and compute continues to grow across life sciences, Sofinnova sees this as a structural shift in how companies are built. This collaboration reflects the firm\u2019s long-term strategy to embed AI into both investment decisions and value creation, while lowering barriers for founders.<\/p><p>\n<b>About <i>Sofia<\/i><br\/><\/b><i>Sofia<\/i> is Sofinnova Partners' proprietary AI platform, developed to support investing and company building in life sciences. It brings together tools for scientific and clinical analysis, market mapping and pitch deck analysis into a single system.<\/p><p>\nPowered by more than 50 years of internal data and continuously enriched through Sofinnova\u2019s investment activity, <i>Sofia<\/i>\u2019s connects researchers, institutions, companies, and investors. It is designed to accelerate how opportunities are identified, evaluated, and scaled.<\/p><p>\n<b>About Sofinnova Partners\n<br\/><\/b>Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.<\/p><p>\nFounded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over \u20ac4 billion in assets. For more information, please visit: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsofinnovapartners.com%2F&amp;esheet=54550147&amp;newsitemid=20260609982334&amp;lan=en-US&amp;anchor=sofinnovapartners.com&amp;index=1&amp;md5=a7683f1d46cbf1c30d6c156276af955b\" rel=\"nofollow\" shape=\"rect\">sofinnovapartners.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Sofinnova Partners<\/b><br\/><b>Bommy Lee<\/b><br\/>Head of Communications\n<br\/><a  href=\"mailto:blee@sofinnovapartners.com\" rel=\"nofollow\" shape=\"rect\">blee@sofinnovapartners.com<\/a><br\/>+33 (0) 6 47 71 38 11<\/p><p>\n<b>Media inquiries:<\/b><\/p><p>\n<b>United Kingdom<\/b><br\/>Optimum Strategic Communications\n<br\/>Eleanor Cooper\n<br\/><a  href=\"mailto:sofinnova@optimumcomms.com\" rel=\"nofollow\" shape=\"rect\">sofinnova@optimumcomms.com<\/a><br\/>+44 (0) 20 4604 4016<\/p><p>\n<b>France<\/b><br\/>Strategies&amp;Image (S&amp;I)\n<br\/>Anne Rein\n<br\/><a  href=\"mailto:anne.rein@strategiesimage.com\" rel=\"nofollow\" shape=\"rect\">anne.rein@strategiesimage.com<\/a><br\/>+33 (0) 6 03 35 92 05<\/p><p>\n<b>Italy<\/b><br\/>Havas PR Milan\n<br\/>Pierluigi Cavarai\n<br\/><a  href=\"mailto:pierluigi.cavaraiext@havaspr.com\" rel=\"nofollow\" shape=\"rect\">pierluigi.cavaraiext@havaspr.com<\/a><br\/>+39 (0) 392 77 999 33<\/p>","protected":false},"excerpt":{"rendered":"<p>Sofinnova combines its sector expertise with AWS\u2019s AI and cloud services to help life sciences companies scale faster<\/p>\n<p>The collaboration expands Sofinnova\u2019s proprietary AI platform, Sofia, including a new founder-facing version<br \/>\nPARIS&#8211;(BUSINESS WIRE)&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18688","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18688"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18688\/revisions"}],"predecessor-version":[{"id":18689,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18688\/revisions\/18689"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}